Canaccord said Amarin remains in active talks with multiple large pharmaceutical and specialty pharmaceutical companies. The firm believes talks are active and that there is significant potential that Amarin will be acquired near-term. The firm rates Amarin a Buy with a $26 price target.
Happy demi-anniversary, stock market rally. Will the honeymoon ever end?